Telatinib (CAS 332012-40-5) Suppliers and Product Information

Telatinib (BAY 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFRα, and c-Kit with IC50 values of 6, 4, 15, and 1 nM, respectively. It is used in research and clinical trials for the treatment of advanced solid tumors.

Frequently Asked Questions about Telatinib

Q: What is the primary mechanism of action of Telatinib?

A: Telatinib is a multi-kinase inhibitor that primarily targets vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/3), platelet-derived growth factor receptor β (PDGFRβ), and c-Kit tyrosine kinases. It works by inhibiting the autophosphorylation of these receptors, thereby interfering with angiogenesis and tumor growth.

Q: What are the potential therapeutic applications of Telatinib?

A: Telatinib has been investigated for the treatment of advanced solid tumors. Clinical trials have explored its use in various cancer types, leveraging its anti-angiogenic properties to potentially inhibit tumor growth and progression.

Q: Are there any notable side effects associated with Telatinib?

A: While individual responses may vary, studies have reported that hypertension and rarefaction (reduction in capillary density) can occur during treatment with Telatinib. As with many kinase inhibitors, careful monitoring of patients is necessary during treatment.